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Auditory neuropathy: a rare disorder?
Auditory neuropathy (AN) is a hearing disorder charac­
terized  by  disruption  of  temporal  coding  of  acoustic 
signals in auditory nerve fibers resulting in impairment of 
auditory  perceptions  that  rely  on  temporal  cues. 
Abnormal  discharge  of  auditory  fibers  results  from 
lesions  involving  the  nerve  fibers  themselves 
(postsynaptic AN), the inner hair cells (IHCs) or their 
synapses with auditory nerve terminals (presynaptic AN) 
[1]. The disruption of auditory nerve discharge underlies 
both the absence of or profound alterations in auditory 
brainstem  responses  and  the  severe  impairment  of 
speech percep  tion. In contrast, cochlear receptor outer 
hair cell (OHC) activities are preserved. This is indicated 
by the detection of otoacoustic emissions (OAEs), which 
are sounds produced by the active contraction of OHCs 
[2], and by recording of cochlear microphonics, which 
result  from  the  vector  sum  of  the  extracellular 
components of the receptor potentials arising in OHCs 
[3].
Auditory  neuropathy  can  be  congenital  or  acquired. 
Congenital AN affects the development of language, an 
ability that is strictly related to the existence of a sensitive 
period  declining  with  age  [4].  In  this  period,  the 
development of language skills is strictly dependent on 
cortical plasticity and requires an efficient auditory input 
[4]. When the onset of AN is delayed to childhood or 
adult life (acquired AN), abnormalities of auditory input 
lead  to  severe  impairment  of  speech  perception  and 
progressive deterioration of acquired language skills [1].
Both the congenital and acquired forms of AN can be 
due to genetic disorders or can have a wide range of other 
etiologies  (for  example,  infections,  toxic  metabolite 
damage or immunological damage) [1,5]. Nevertheless, 
no  etiologic  factors  can  be  identified  in  approximately 
half of the patients [1]. All forms of the disorder may be 
present in isolation (isolated AN) or be associated with 
multisystem involvement (non­isolated AN).
Auditory neuropathy occurs in all age groups [1] and 
its reported prevalence varies from 1% to 10% [6]. This 
high variability may reflect the inclusion in some studies 
of diseases in which the AN disorder is transient, such as 
Guillain­Barré  syndrome  [5].  Moreover,  in  neonates 
admitted to neonatal intensive care units showing absent 
auditory brainstem responses and the presence of OAEs 
at newborn hearing screening [7], the brainstem response 
abnormalities  may  reflect  delayed  maturation  of  both 
brainstem and auditory nerve generators. On the other 
hand, some hearing disorders underlying AN might not 
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identification of the AN picture in cooperative patients 
may require several tests to be performed in addition to 
hearing­threshold  evaluation,  and  these  are  not  in­
variably  included  in  routine  diagnosis.  Refined  diag­
nostics  together  with  progress  in  genetic  research  will 
provide a more accurate calculation of the prevalence of 
AN disorders and, among them, of forms with a genetic 
etiology.
Clinical  criteria  for  diagnosis  include  impairment  of 
speech perception beyond that expected for hearing loss, 
the absence or marked abnormality of auditory brainstem 
responses and preserved OHC activities (OAEs and/or 
cochlear  microphonics).  Nevertheless,  some  patients 
with  AN  may  have  normal  hearing  thresholds  and  an 
impairment of speech perception that is only apparent in 
the presence of noise [1]. In these subjects the evaluation 
of  speech  perception  in  noise  and  psychoacoustical 
testing (gap detection, frequency discrimination) [8] are 
mandatory.  Cochlear  implantation  constitutes  the  only 
rehabilitative  tool  able  to  restore  speech  perception  in 
patients affected by presynaptic AN [9] or in postsynaptic 
AN  localized  to  the  distal  portions  of  auditory  nerve 
fibers [10,11].
In the past decade, the identification of several genes 
involved  in  the  pathogenesis  of  both  presynaptic  and 
postsynaptic AN has greatly contributed to the diagnosis 
and better understanding of mechanisms underlying this 
disorder. This review will provide a description of all the 
genes so far discovered to be involved in the pathology of 
auditory  neuropathy,  including  those  most  recently 
identified such as DIAPH3, OTOF and OPA1. The effects 
of the abnormal function of gene products at the cellular 
level, the histopathologic findings in animal models, and 
electrophysiological  recordings  obtained  from  patients 
carrying  specific  gene  mutations  will  be  reviewed. 
Moreover, possible mechanisms underlying the alteration 
of  auditory  nerve  discharge  will  be  discussed  for 
mutations of individual genes.
The genetic disorders underlying auditory 
neuropathy
All the genes and loci implicated in the pathogenesis of 
AN  so  far  are  listed  in  Table  1  under  the  categories 
isolated AN or non­isolated AN.
Genes involved in isolated AN
Specific gene mutations underlying isolated AN consti­
tute a unique opportunity to relate AN to specific altera­
tions in single­cell function and metabolism. Of these, 
mutations in the OTOF gene with a recessive pattern of 
inheritance  are  the  best  known.  It  has  been  estimated 
that these mutations are responsible for at least 3% of 
cases of prelingual non­syndromic hearing impairment 
in  the  Spanish  population  [12,13].  OTOF  encodes 
otoferlin,  a  transmembrane  protein  belonging  to  the 
ferlin protein family, which contains several repeating C2 
domains involved in calcium binding [14]. Otoferlin plays 
a crucial role in vesicle release at the synapse between 
IHCs  and  auditory  nerve  fibers  by  interacting  with 
syntaxin1  and  SNAP25  [15],  and  it  has  recently  been 
implicated  in  vesicle  replenishment  at  the  presynaptic 
membrane [16]. To date, more than 40 pathogenic muta­
tions  of  the  OTOF  gene  have  been  identified  [13],  all 
resulting in a very homogeneous phenotype of prelingual, 
profound  hearing  loss  with  an  absence  of,  or  marked 
threshold  elevation  of,  auditory  brainstem  responses. 
More than 50% of subjects carrying biallelic OTOF muta­
tions also show preserved function of OHCs as indicated 
by OAE recording [13]. The absence of OAEs in half the 
patients with OTOF mutations does not rule out AN, as 
the disappearance of OAEs over time has been reported 
in  several  AN  disorders  as  possibly  reflecting  delayed 
involvement of OHCs in the pathological process [1].
Missense mutations in the PJVK gene associated with 
AN  have  been  identified  with  a  recessive  pattern  of 
inheritance  in  four  Iranian  families  whose  affected 
members showed congenital profound hearing loss and 
presence  of  OAEs  [17].  PJVK  encodes  pejvakin,  a 
352­residue protein belonging to the gasdermin protein 
family,  localized  in  the  hair  cells,  supporting  cells  and 
spiral  ganglion  neurons,  whose  function  remains  un­
known  [17].  Nevertheless,  the  association  of  AN  and 
PJVK  gene  mutations  has  been  questioned  [18],  as  no 
OAEs  have  been  obtained  from  families  carrying  the 
same mutations as those reported in [17], while trun  cat­
ing mutations in the PJVK gene may be associated with 
progressive hearing loss without OAE detection [19].
An autosomal dominant auditory neuropathy, AUNA1, 
has been identified in an American family of European 
descent  whose  affected  members  showed  moderate 
hearing loss beginning in the second decade of life and 
progressing to severe deafness in the fifth decade [11]. 
Due to improvement of auditory functions and restora­
tion  of  electrically  evoked  brainstem  potentials  after 
cochlear  implantation,  abnormal  function  of  the  distal 
portion  of  auditory  nerve  fibers  was  hypothesized. 
Recently, a point mutation (c.­172G>A) has been identified 
in a highly conserved region (5’ UTR) of the  DIAPH3 
gene of the affected members. The DIAPH3 gene is one 
of the three human orthologs of Drosophila Diaphanous 
and encodes a protein belonging to the formin protein 
family [20]. This is an actin­nucleation factor implicated 
in the maintenance of cell and stereocilium shape, vesicle 
trafficking, and other cell activities through the regulation 
of actin polymerization [21]. DIAPH3 mutation leads to 
an overexpression of DIAPH3 protein [20], which may 
result in an alteration in shape of the dendritic spines in 
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delayed  impairment  of  hair­cell  function,  leading  to 
profound deafness and disappearance of OAEs over time.
A mutation (T1095C) in a highly conserved region of 
the mitochondrial 12S rRNA gene has been identified in 
a Chinese patient with moderate deafness and showing 
the picture of isolated AN [23]. It has been hypothesized 
that  the  phenotypic  expression  of  this  mutation  was 
influenced by two more genetic variants identified in the 
same gene in a highly conserved region.
Genes involved in non-isolated AN
It has been estimated that over one third of subjects with 
AN are affected by peripheral neuropathies [6]. In addi­
tion, optic neuropathies and other CNS disorders have 
been  found  in  association  with  AN  (non­isolated  AN, 
Table 1). In this group of subjects the hearing disorder is 
underlain  by  several  genetic  defects,  all  resulting  in 
neuronal  loss  and  demyelination  in  peripheral  and/or 
cranial  nerves,  and  the  site  of  the  lesion  is  invariably 
postsynaptic.
AN has been identified at relatively high frequency in 
patients  affected  by  Charcot­Marie­Tooth  (CMT) 
disease. The first gene associated with AN in this group 
was the myelin protein zero (MPZ) gene [24] encoding a 
protein  included  in  the  compact  myelin  that  plays  a 
crucial  role  in  myelin  formation  and  adhesion.  A 
missense  mutation  in  MPZ  was  identified  in  a  family 
affected  by  dominant  AN  and  demyelinating  sensori­
motor  neuropathy  [24].  Post­mortem  examination 
carried  out  on  one  member  of  this  family  revealed 
preserved hair cells in the cochlea, a marked decrease in 
spiral ganglion cell number and extensive degeneration of 
both  peripheral  and  central  processes  in  the  residual 
axons. Moreover, the proximal portion of the auditory 
nerve showed axonal loss and incomplete remyelination 
at the entrance to the brainstem similar to that found on 
histological examination of the sural nerve in the same 
patient. Notice that the patient was affected by peripheral 
neuropathy  and  thus  postmortem  examination  was 
carried out on both cranial and peripheral nerves. These 
findings are relevant as they confirm the hypothesis that 
both  axonal  loss  and  demyelination  of  auditory  nerve 
fibers  underlie  the  disruption  of  temporal  coding  of 
acoustic  signals  through  reduced  input  and  slowed 
conduction of action potentials. The involvement of the 
entire  auditory  nerve  associated  with  hair­cell  preser­
vation is likely to be a feature shared by the majority of 
AN  disorders  included  in  the  CMT  group.  This  has 
implications for the outcome of cochlear implantation, as 
Table 1. Genes and loci implicated in the pathogenesis of auditory neuropathy (AN) with corresponding phenotypes
Syndrome name  Locus  Gene  Transmission  Phenotype  Reference
Isolated AN
  2p23-p22  OTOF  Recessive  Congenital profound deafness  [9,12]
  2q31.1-q31.3  PJVK  Recessive  Congenital profound deafness  [17]
AUNA1  13q21-q24  DIAPH3  Dominant  Moderate to profound deafness  [11,20]
  mtDNA  12S rRNA (T1095C)    Moderate deafness  [23]
Non-isolated AN
CMT 1A  17p11.2-p12  PMP22  Dominant  Mild to severe deafness; demyelinating neuropathy  [25]
CMT 1B  1q22  MPZ  Dominant  Mild to severe deafness; demyelinating neuropathy  [24]
CMT 2E  8p21  NF-L  Dominant  Normal hearing; axonal neuropathy  [29]
CMT 4D  8q24.3  NDRG1  Recessive  Mild to severe deafness; axonal/demyelinating neuropathy  [26,27]
CMT  1p34  GJB3 (Cx31)  Dominant  Mild deafness  [30]
CMT 1X  Xp13  GJB1 (Cx32)  X-linked Dominant  Demyelinating neuropathy  [31]
ADOA  3q28-q29  OPA1 (R445H)  Dominant  Optic neuropathy; moderate deafness  [36]
AROA  11q14.1-11q22.3  TMEM126A  Recessive  Optic neuropathy; mild hearing loss  [42]
Friedreich’s ataxia  9q13  FXN  Recessive  Ataxia; axonal neuropathy; optic neuropathy;   [43]
        cardiomyopathy; normal hearing threshold; mild deafness
AUNX1  Xq23-q27.3    X-linked Recessive  Sensory axonal neuropathy; mild-to-severe deafness  [46]
DDON (Mohr-Tranebjaerg)  Xq22.1  TIMM8A  X-linked Recessive  Progressive deafness; dystonia, optic neuropathy; dementia  [45]
Wolfram  4p16.1  WFS1  Recessive  Optic atrophy, diabetes, progressive deafness, dementia  [47]
LHON (Leber)  mtDNA  MTND4 (11778mtDNA)    Optic neuropathy; mild-to-moderate deafness  [41]
ADOA, autosomal dominant optic atrophy; AROA, autosomal recessive optic atrophy; AUNA1, Autosomal dominant auditory neuropathy; AUNX1, auditory 
neuropathy, X-linked recessive; CMT, Charcot-Marie-Tooth; DDON, deafness dystonia optic neuronopathy; LHON, Leber’s hereditary optic neuropathy.
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delayed  conduction  of  neural  impulses  in  residual 
auditory nerve fibers are expected. A point mutation of 
the PMP22 gene, which encodes another protein included 
in  compact  myelin,  has  been  found  in  a  family  whose 
affected  members  showed  demyelinating  neuropathy 
associated with the clinical picture of AN [25].
Two more genes associated with the CMT group of AN 
are of particular interest. One is the N­myc downstream­
regulated gene 1 (NDRG1), which encodes a protein that 
shuttles  between  the  cytoplasm  and  the  nucleus  in 
Schwann cells and has been implicated in cell differen­
tiation and maintenance [26]. Point mutations in NDRG1 
underlie  a  recessive  axonal  and  demyelinating  sensori­
motor  neuropathy  which  has  been  associated  with  the 
picture of AN [26,27]. Another gene associated with AN 
is  NF-L,  which  is  involved  in  the  molecular  processes 
underlying  neuronal  plasticity  by  encoding  a  protein 
involved  in  axonal  sprouting  [28].  Two  different  point 
mutations have recently been identified in NF-L in two 
Slovenian  families  whose  members  were  affected  by 
axonal neuropathy [29]. One of these families presented 
with  the  picture  of  AN.  Interestingly,  the  affected 
members showed abnormal auditory brainstem res  ponses 
associated with OAE detection but without impair  ment 
of  speech  perception  and  gap  detection  abilities. 
Although  mutations  in  both  GJB1  and  GJB3  (which 
encode gap junction proteins) have been associated with 
AN [30,31], the reported evidence does not allow us to 
definitely identify the AN pattern in the affected patients 
described so far.
Several types of optic neuropathies have proved to be 
associated with AN. Among these, autosomal dominant 
optic  atrophy  is  underlain  by  mutations  in  the  OPA1 
gene,  which  encodes  a  dynamin­related  mitochondrial 
GTPase  involved  in  the  regulation  of  oxidative  phos­
phory  lation [32], mitochondrial fusion [33], maintenance 
of integrity of mitochondrial cristae [34], and control of 
apoptosis [35]. To date, AN has been associated only with 
the Arg445 to His (R445H) mutation [10,36], although 
sensorineural  hearing  loss  has  been  reported  in  more 
than  50%  of  patients  carrying  OPA1  mutations  [37]. 
Unfortunately,  no  extensive  audiological  and  electro­
physio  logical studies were carried out in the majority of 
affected  subjects  to  better  characterize  the  hearing 
disorder. Combined electrophysiological and audiological 
evaluation on two related patients carrying the R445H 
mutation [10] suggest that the lesion involves the distal 
portion  of  auditory  nerve  fibers.  This  hypothesis  is 
supported by a mouse model of OPA1 showing dendritic 
pruning of the optic nerve fibers at the early stage of the 
disease [38]. Extensive demyelination of the entire optic 
and  auditory  nerves  has  been  found  on  post­mortem 
examination  in  two  elderly  patients  with  advanced 
disease  [39].  These  findings,  together  with  the  loss  of 
retinal ganglion cells and degeneration of residual axons 
found in another mouse model [40], would suggest that 
demyelination and axonal loss affecting the whole optic 
and auditory nerves constitutes a more advanced stage of 
the  disease  compared  to  the  stage  of  dendritic  tree 
pruning [38].
Auditory neuropathy has also been well documented in 
two  patients  with  Leber’s  hereditary  optic  neuropathy, 
which  is  underlain  by  a  mitochondrial  point  mutation 
[41],  and  in  patients  with  autosomal  recessive  optic 
atrophy due to nonsense mutations of the TMEM126A 
gene encoding a mitochondrial protein [42]. In general, 
the  association  of  optic  and  auditory  neuropathies  in 
patients with abnormal mitochondrial function may be 
considered in the light of the high metabolic demands of 
specific  neural  structures  such  as  the  unmyelinated 
portion of both optic and auditory nerve fibers. Unlike in 
myelinated axons, in which the conduction of impulses is 
saltatory, electrical conduction in the unmyelinated fibers 
is electrotonic and energy consuming.
Impairment of speech perception has been found with 
high frequency in patients affected by Friedreich’s ataxia 
and has been related to AN  [43]. Friedreich’s ataxia is 
underlain by a GAA trinucleotide repeat expansion in the 
FXN gene with consequent reduction of gene expression, 
which results in mitochondrial iron overload [44] in both 
peripheral nerves and the CNS. The majority of patients 
with Friedreich’s ataxia show a picture of AN with normal 
hearing  threshold  and  remarkable  decrease  in  speech 
perception abilities [43].
Among the multisystem disorders, the Mohr­Tranebjaerg 
syndrome  (deafness  dystonia  optic  neuronopathy)  pro­
vides a good example of AN that has been assessed on a 
histopathologic  basis.  Post­mortem  specimens  obtained 
from four patients with AN [45] revealed extensive loss of 
spiral  ganglion  neurons  with  preservation  of  hair  cells. 
Neuronal loss in these patients is expected to be due to the 
abnormal function of a protein encoded by the TIMM8A 
gene on the X chromosome and embedded in the inner 
mitochondrial membrane. The X chromosome also con­
tains the locus underlying AN in a large Chinese family 
whose members are affected by postlingual hearing loss 
and  progressive  peripheral  sensory  neuro  pathy  [46]; 
however, the underlying gene has not yet been identified.
Finally,  AN  has  been  identified  on  a  histopathologic 
basis  in  young  patients  with  Wolfram  syndrome  [47]. 
Post­mortem examination showed extensive phenomena 
of brain atrophy and axonal loss involving both auditory 
and optic nerves.
Mechanisms underlying auditory neuropathy
Figure 1 illustrates schematically the possible patho  physio­
logical  mechanisms  underlying  genetically  based  AN.  In 
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impaired because of the disruption of temporal coding of 
acoustic  signals  [8].  In  the  healthy  cochlea,  temporal 
precision  of  acoustic  signaling  is  guaranteed  by  the  fast 
kinetics  of  synaptic  release,  postsynaptic  mem  brane 
activation, and the initiation and propagation of spikes along 
the auditory nerve fibers [48]. Fast vesicle release, which is 
triggered  by  calcium  influx  through  one  or  two  calcium 
channels [49], tight coupling of these channels to the vesicle­
release sites [49], and parallel release of multiple vesicles 
through the ribbons [50], all ensure high rate and temporal 
precision of release of the neurotransmitter glutamate. In 
particular, multivesicular release guarantees the generation 
of excitatory post  synaptic potentials (EPSPs) of sufficient 
amplitude to trigger spike initiation in the auditory nerve 
fibers  [48].  The  disruption  of  any  of  these  presynaptic 
mechanisms impairs the precision of temporal coding and/
or the reliability of synaptic transmission with consequent 
decrease in the amplitude and rise time of EPSPs.
A  typical  example  of  presynaptic  disorder  leading  to 
the clinical picture of AN is that caused by the abnormal 
function  of  otoferlin.  Reduced  activity  of  this  protein 
leads  to  a  reduced  rate  of  vesicle  replenishment  [51], 
which in the healthy cochlea is a very fast process, and 
abolition  of  the  fast  phase  of  exocytosis  [15].  The 
decrease in neurotransmitter release is likely to result in a 
decrease in amplitude of EPSPs with decreased synaptic 
reliability. This may explain why patients with mutations 
in  OTOF  usually  present  with  profound  hearing  loss. 
Nevertheless,  the  slow  component  of  exocytosis  is  not 
abolished  [15],  while  recordings  of  cochlear  neural 
potentials from patients with OTOF mutations ([52], see 
below) point to activation of the postsynaptic membrane. 
Given  this,  it  could  be  hypothesized  that,  besides  the 
reduction of neurotransmitter availability at the synaptic 
cleft,  there  is  an  impairment  of  multivesicular  release 
which  leads  to  the  generation  of  small  EPSPs  with 
abnormal  morphology  and  dispersed  in  time.  These 
Figure 1. Possible mechanisms underlying presynaptic or postsynaptic auditory neuropathy. In the healthy cochlea (Normal) an auditory 
input transmitted from an outer hair cell (OHC) evokes a synchronized discharge of auditory nerve fibers. In presynaptic AN, both the reduction 
and the increased time of neurotransmitter release result in decreased postsynaptic activation (decreased input) and elicitation of EPSPs with 
abnormal morphology leading, in turn, to a reduction of occurrence of and increased time to spike initiation (desynchrony). This mechanism is 
likely to underlie AN in patients carrying OTOF mutations. In postsynaptic AN, there is a decrease in activated auditory fibers (decreased input), 
abnormalities in spike occurrence with slowing in conduction velocity, which results in loss of temporal precision and stimulus correlation of 
auditory nerve fiber discharge (desynchrony). Genes implicated in pre- and postsynaptic AN, respectively, are shown in the boxes.
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are expected to be poorly related to acoustic stimuli. This 
hypothesis  is  supported  by  the  identification  of  some 
patients with OTOF mutations who show almost normal 
hearing thresholds together with severe impairment of 
speech  perception  (R.  Santarelli  et  al.,  manuscript  in 
preparation).
Although PJVK protein has been localized in hair cells, 
supporting cells and spiral ganglion neurons, its function 
remains unknown; thus, it is not possible to suggest any 
mechanisms underlying AN in patients with mutations in 
the PJVK gene.
In  the  healthy  cochlea,  both  the  postsynaptic  mem­
brane and the auditory nerve fibers are adapted for fast 
and  precise  signal  transmission.  Like  the  synapses 
between rods and bipolar cells in the optic nerve, AMPA 
receptors  on  the  postsynaptic  membrane  of  auditory 
nerve  fibers  show  low  affinity  for  glutamate  [53].  This 
results in rapid activation and deactivation of the post­
synaptic membrane, while the low tendency to receptor 
desensitization ensures that the nerve fibers retain their 
sensitivity  in  spite  of  the  high  amounts  of  glutamate 
released  in  the  synaptic  cleft  [48].  Moreover,  the 
abundance of Nav1.6 sodium channels and their strategic 
disposition along the nerve fibers enhances the velocity 
and precision of spike initiation and propagation [54].
The demyelination of auditory nerve fibers observed in 
demyelinating  neuropathies  is  expected  to  result  in 
slowed conduction velocity with consequent disruption 
of temporal coding of acoustic signals (desynchrony) [8], 
while the decrease in number of nerve fibers found in 
axonal neuropathies would result in a reduced auditory 
input to the brainstem. However, this is a simplified view 
of the alterations of auditory nerve discharge, as slowing 
of  conduction  velocity  and  reduction  of  neural  fiber 
recruitment might interact and disrupt the ‘spectrum’ of 
discharges of auditory nerve fibers activated by a specific 
acoustic signal. Moreover, it is reasonable to hypothesize 
that the residual axons are not functioning properly, as 
they show abnormal spike initiation and conduction. All 
these  mechanisms  are  likely  to  be  involved  in  the 
pathophysiology  of  several  axonal  and  demyelinating 
auditory  neuropathies  such  as  those  underlain  by 
mutations in the MPZ, PMP22 and NDRG1 genes.
In  general,  all  the  genetic  disorders  leading  to  an 
abnormal  mitochondrial  function  cause  dysfunction  of 
the unmyelinated portion of auditory nerve fibers, which 
may represent the first sign of disease. This is likely to 
result from the high metabolic demands of unmyelinated 
axons for spike conduction. Abnormalities of the distal 
portion of auditory nerve fibers have been hypothesized 
as underlying AN in patients carrying the OPA1 mutation 
[11,20], and dendritic pruning of optic nerve fibers is the 
first sign of disease in animal models of OPA1 [38].
It is important to emphasize that the AN associated 
with specific gene mutations may be caused by several 
mechanisms  interacting  with  each  other,  and  the 
distinction between pre­ and postsynaptic AN should be 
treated  with  caution.  For  instance,  demyelination  and 
axonal loss have been found in the advanced stages of 
disease due to mutant OPA1 [39] and in some experi­
mental models of OPA1 [40]; this indicates that dendritic 
dysfunction is not the only mechanism involved in the 
pathophysiology of AN in these gene disorders. More­
over, some forms of AN showing postsynaptic dysfunc­
tion as the first sign of disease may turn into disorders 
with  prevalent  presynaptic  involvement.  For  instance, 
patients carrying the DIAPH3 mutation show moderate 
hearing loss associated with severe impairment of speech 
perception [11], which has been explained as resulting 
from dysfunction of the dendritic spines contacting the 
IHCs  [11,20].  Thereafter,  the  hearing  impairment  pro­
gresses to profound deafness and OAEs disappear [11]. 
At this late stage, there is likely to be involvement of the 
stereocilia in both IHCs and OHCs, as the DIAPH3 gene 
is known to regulate the activity of presynaptic actin and 
microtubule cytoskeletons in the neuromuscular junction 
of Drosophila [55].
Diagnosis of auditory neuropathy: a true challenge
In  AN,  the  impairment  of  spike  initiation,  reduced 
auditory  input  due  to  axonal  loss,  and  slowing  in 
conduction velocity related to demyelination of residual 
nerve fibers result in disruption of auditory nerve dis­
charge  and  auditory  brainstem  response  abnormalities 
beyond  those  expected  from  the  hearing  loss  [1].  The 
same pathological processes underlie the impairment of 
speech perception, which is reduced out of proportion to 
the  elevation  in  hearing  threshold.  In  general,  affected 
subjects show decreased performance in all the auditory 
tasks  that  rely  on  temporal  coding  of  acoustic  signals 
such as gap detection and low­frequency discrimination 
[8]. OAEs are detected in typical cases as long as OHCs 
are preserved. If all these findings are present, the diag­
nosis  of  AN  is  straightforward,  particularly  in  the 
presence of concomitant peripheral and/or optic neuro­
pathy.  Moreover,  the  identification  of  specific  gene 
mutations may help to localize the lesion and has impli­
cations  for  rehabilitation,  which  sees  cochlear  implan­
tation  as  the  only  tool  for  the  restoration  of  speech 
perception by bypassing the site of the lesion.
However,  OAEs  are  absent  in  more  than  a  third  of 
patients  on  re­testing  [1],  and  impairment  of  speech 
perception may be apparent only in the presence of noise 
[1]. Moreover, no detailed information of cochlear nerve 
and  hair­cell  activities  can  be  provided  by  auditory 
brainstem response recording because of the low signal­
to­noise  ratio.  Recently,  the  use  of  transtympanic 
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details  of  cochlear  potentials  including  both  receptor 
activities (measured as summating potential and cochlear 
microphonics) and auditory nerve activities (measured as 
the compound action potential) [56]. Figure 2 shows two 
transtympanic  electrocochleogram  patterns  obtained 
from patients with AN who each carried a mutation in a 
different gene: OTOF [52] and OPA1 [10]. The cochlear 
potentials  observed  in  response  to  clicks  were 
superimposed  on  the  grand  average  of  the  summating 
potential­compound action potential responses obtained 
from 16 controls with normal hearing at 120 dB peak­
equivalent  sound  pressure  level.  In  controls,  the  sum­
mating  potential  was  followed  by  a  straight  neural 
response with mean latency of 1.5 ms. In patients with 
OPA1 or OTOF mutations, the responses arising in the 
auditory  nerve  consisted  of  negative  potentials  with 
reduced  amplitude,  increased  latency  and  prolonged 
duration  compared  to  controls.  Nevertheless,  several 
differ  ences  between  OPA1  and  OTOF  subjects  were 
found. First, the prolonged potentials were recorded as 
low as 50­90 dB below behavioral thresholds in subjects 
with  OTOF  mutations,  whereas  in  the  OPA1  disorder 
they were correlated with hearing threshold (not shown). 
Moreover,  a  low­amplitude  compound  action  potential 
was superimposed on the prolonged responses at high 
stimulus  intensity  in  the  subject  with  biallelic  OTOF 
mutation, while no such potential was identified in the 
OPA1  patient.  Finally,  electrically  evoked  compound 
action  potentials  were  recorded  after  cochlear  implan­
tation only from the child carrying biallelic mutation in 
the  OTOF  gene.  From  these  observations  it  can  be 
hypothesized that the low­threshold prolonged potentials 
recorded  in  OTOF  disorders  are  related  to  abnormal 
neurotransmitter release resulting in reduced dendritic 
activation  and  impairment  of  spike  initiation,  whereas 
the  lack  of  both  acoustically  and  electrically  evoked 
compound  action  potentials  in  the  OPA1  disorder  is 
consistent with abnormal function of the distal portions 
of auditory nerve fibers.
In conclusion, the diagnosis of AN relies on objective 
tests as well as on tests requiring the cooperation of the 
patient.  However,  it  is  the  whole  body  of  findings 
collected  using  several  techniques  that  contributes  to 
defining the disorder and helps to localize the underlying 
lesion. The correlation between electrophysiological and 
Figure 2. Cochlear potentials recorded from patients with mutations in the OTOF or OPA1 gene. The upper panels show recordings from 
two subjects carrying, respectively, the R445H mutation in OPA1 and biallelic mutations in OTOF. The recordings (black line) are superimposed on 
the mean summation potential-compound action potential (SP-CAP) response (gray line) from 16 controls with normal hearing at 120 dB sound 
pressure level intensity. The shaded area indicates the 95% confidence limit. The CAP response observed in controls is replaced in AN patients by 
a low-amplitude prolonged negative deflection following the SP. A small CAP (arrowed) is superimposed on the sustained response only in the 
child carrying biallelic OTOF mutation. The lower panels show the electrically evoked neural potentials (e-CAP) recorded through cochlear implant. 
A neural response was obtained only from patients with OTOF mutations.
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clarify  the  mechanisms  underlying  AN  in  individual 
patients. For instance, a picture of profound hearing loss 
associated  with  the  presence  of  slow  negative  compo­
nents  at  low  stimulation  intensities  in  electrocochleo­
graphy recordings points to a presynaptic disorder with 
reduced dendritic activation and preserved function of 
auditory  nerve  fibers.  A  severe  visual  impairment 
associated with the AN picture and the presence of slow 
negative potentials in electrocochleogram waveforms at 
intensities  related  to  hearing  thresholds  suggests  a 
postsynaptic  disorder  involving  the  distal  portions  of 
auditory  nerve  fibers,  possibly  underlain  by  an  OPA1 
mutation or a mitochondrial disorder.
The identification of specific mutations underlying AN 
has  implications  not  only  for  diagnosis  but  also  for 
rehabilitation,  as  cochlear  implantation  is  expected  to 
have a good outcome when the disorder is due to muta­
tions  underlying  presynaptic  (OTOF)  and  post  synaptic 
(OPA1 and DIAPH3) disorders in the distal portions of 
auditory  fibers.  In  contrast,  cochlear  implantation  is 
expected to have little benefit in forms of AN involving 
the entire auditory nerve.
Future developments
Auditory neuropathies constitute a fascinating group of 
hearing  dysfunctions  in  that  the  definition  of  their 
pathophysiology and site of lesion involves the collection 
of  findings  from  psychoacoustics,  evoked­potential 
record  ings,  genetics,  molecular  biology  and  animal 
models.  Identification  of  mutations  in  specific  genes 
associated with typical electrophysiological patterns and 
the  comparison  of  these  findings  with  those  obtained 
from animal models may be the key factor in revealing 
how the failure of different molecular processes underlies 
the varieties of AN. Studies focusing on the function of 
proteins encoded by specific genes at cellular level, the 
effects of abnormal functions of these proteins in animal 
models,  the  combination  of  information  from  basic 
research  with  audiological  and  electrophysiological 
findings in patients carrying mutations in specific genes, 
are all expected to improve diagnosis in the near future 
with  regard  to  both  site  of  lesion  and  mechanisms 
involved. In particular, the use of electrocochleographic 
recordings could help in bridging knowledge from basic 
research  and  clinical  evaluation.  Improvements  of  this 
technique from the point of view of frequency selectivity 
and recording from a small group of fibers together with 
the combination of the electrocochleogram results with 
those  provided  by  electrically  evoked  potential 
recordings would contribute to better characterization of 
the lesion in the auditory periphery.
A  second  crucial  point  would  be  to  perform  brain­
imaging  studies  aimed  at  identifying  specific  brain 
regions with abnormal responses to specific stimuli such 
as  speech  in  noise,  brief  silent  periods  in  noise,  and 
sounds  with  different  frequency  content.  Finally,  it 
remains to be assessed whether different mutations of 
the same gene result in similar phenotypes, or whether 
differences  in  amounts  and  activity  of  the  synthesized 
protein, if present, might result in different patterns of 
auditory  nerve  discharge.  In  other  words,  knowledge 
from basic research should be combined with clinical, 
audiological, psychoacoustical, electrophysiological, and 
imaging studies in humans to characterize the lesion at 
the  level  of  the  auditory  periphery  and  the  changes 
induced in auditory brain areas by the abnormal input 
from lower auditory centers.
The only effective treatment for restoration of speech 
perception in AN is cochlear implantation. However, the 
outcome of cochlear implantation varies widely among 
patients. While it is generally acknowledged that patients 
with presynaptic AN due to mutations in the OTOF gene 
invariably benefit [9], a poor outcome has been reported 
for implanted subjects with postsynaptic AN underlain 
by  axonal  loss  and  degeneration  of  the  entire  nerve 
fibers, as in Friedreich ataxia [57] and deafness dystonia 
optic  neuronopathy  [58].  In  contrast,  two  patients 
carrying the R445H mutation in the OPA1 gene [10] and 
some subjects with mutations in the DIAPH3 gene [11] 
showed  restoration  of  both  speech  perception  and 
auditory  brainstem  responses  following  cochlear 
implantation. In these subjects the electrical stimulation 
provided through the cochlear implant is presumed to 
bypass  the  site  of  the  lesion,  which  is  limited  to  the 
terminal  dendrites.  In  this  view,  the  identification  of 
specific genetic mutations is crucial to deciding whether 
to perform cochlear implan  tation. However, whether or 
not specific strategies of electrical stimulation possibly 
tailored  on  the  abnormal  discharge  of  demyelinated 
fibers  could  improve  speech  perception  in  implanted 
patients  with  demyelinating­axonal  neuropathies 
remains  to  be  assessed.  Recently,  children  with 
Friedreich’s ataxia have received significant benefit from 
using  an  FM­listening  device  in  everyday  life  and  in 
speech  perception  performance  [59].  FM­systems 
transmit the speech signals detected by a microphone, 
which is worn by the speaker, to the ear receivers worn 
by the listeners. In this regard, a further possibility worth 
exploring as a rehabilitative strategy is pre­processing of 
acoustic signals to make them more suited for eliciting a 
‘meaningful’ input from the auditory periphery.
In  conclusion,  the  combination  of  findings  from 
genetic research and highly sensitive neurophysiologic 
record  ings  will  help  clarify  both  the  mechanisms  and 
the  anatomical  sites  underlying  the  disruption  of 
temporal coding of sounds in auditory nerve fibers that 
is typical of AN.
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